?
Reliability of immune receptor rearrangements as genetic markers for minimal residual disease monitoring
Bone Marrow Transplantation. 2016. Vol. 1. No. 3.
Назаров В. И., Minervina A. A., Komkov A. Y., Pogorelyy M., Maschan M. A., Olshanskaya Y. V., Zvyagin I., Chudakov D., Lebedev Y. B., Mamedov I.
Detection of minimal residual disease (MRD) is a powerful prognostic tool in many hematological malignancies including ALL.1 Several groups of markers are widely used to monitor the concentration of a malignant clone including the detection of 'clonal B-cell (BCR) or T-cell (TCR) gene receptor rearrangements2 in ALL. Identification of a clonal rearrangement specific for the malignant clone, which usually constitutes from 20 to 90% in the initial bone marrow sample is a relatively straightforward task. Tracking this rearrangement after therapy is more tricky as the concentration of malignant cells in the sample can be very low.
Приоритетные направления:
компьютерно-математическое
Язык:
английский